Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Universal everolimus for malignant neuroendocrine tumours?

Neuroendocrine neoplasms are a heterogeneous group of malignant tumours which vary in localisation, clinical presentation, tumour biology, and prognosis. The tumours derive from the diffuse neuroendocrine cell system, which is spread all over the body. The main tissues affected are thymus, lungs, gastrointestinal tract, and pancreas. Some tumours present clinical syndromes related to peptide and amine production with clinical syndromes like gastrinoma, insulinoma, VIPoma, and glucagonoma syndromes, and the carcinoid syndrome related to serotonin and tachykinin production from small intestinal neuroendocrine tumours (carcinoids).